Last €80.18 EUR
Change Today -0.25 / -0.31%
Volume 205.2K
SAN On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 3:33 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi (SAN) Snapshot

Open
€80.14
Previous Close
€81.25
Day High
€80.43
Day Low
€79.58
52 Week High
09/30/14 - €89.95
52 Week Low
02/6/14 - €68.29
Market Cap
106.1B
Average Volume 10 Days
4.5M
EPS TTM
€3.12
Shares Outstanding
1.3B
EX-Date
05/12/14
P/E TM
25.6x
Dividend
€2.80
Dividend Yield
3.48%
Current Stock Chart for SANOFI (SAN)

sanofi (SAN) Details

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances and collaborations with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., Medtronic, Inc., UCB S.A., and Illumina, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1970

sanofi (SAN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €3.0M
Compensation as of Fiscal Year 2013.

sanofi (SAN) Key Developments

Amgen Files Lawsuit Against Sanofi, Aventisub LLC and Regeneron Pharmaceuticals, Inc. for Patent Infringement

Amgen announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively Sanofi), and Regeneron Pharmaceuticals, Inc. (Regeneron) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9). By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S.

Selecta, JDRF and Sanofi Extend Collaboration to Develop Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

Selecta Biosciences, Inc., and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. This collaborative research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas. As part of their collaboration, JDRF and Sanofi are co-financing the program with the aim of advancing the SVP product candidate to the clinic. This next phase of the SVP development program has been structured as a grant award to Selecta in order to test up to four antigens that may succeed in stopping the autoimmune response that destroys beta cells.

Sanofi's $7.9 Billion Portfolio Sale Reportedly In Limbo

Sanofi (ENXTPA:SAN)'s plan to sell or find partners for an $7.9 billion portfolio of established drugs is at a standstill amid disagreements among top managers as to how to move forward, Bloomberg reported citing people familiar with the matter. The assets have not been carved out into a separate business unit and management hasn’t decided what to keep or let go. Sanofi has no financial details to present to parties interested in the European portfolio. A spokesman for Sanofi declined to comment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAN:FP €80.18 EUR -0.25

SAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $54.41 USD +1.04
Amgen Inc $137.51 USD +3.82
Bayer AG €102.40 EUR -0.36
Gilead Sciences Inc $102.21 USD +1.46
Novo Nordisk A/S kr259.20 DKK -1.60
View Industry Companies
 

Industry Analysis

SAN

Industry Average

Valuation SAN Industry Range
Price/Earnings 24.4x
Price/Sales 3.0x
Price/Book 1.9x
Price/Cash Flow 14.8x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit www.sanofi-aventis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.